Approach to the genetic evaluation of the child with autism

Pediatric Clinics of North America

Volumn 59, Issue 1, 2012, Pages 113-128

  Toriello, Helga V ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b SPECTRUM HEALTH   (United States)

Author keywords

Autism spectrum disorders; Diagnosis; Family history; Microarray; Syndrome

Indexed keywords

CARRIER PROTEIN; CHOLESTEROL; CREATINE; CREATINE TRANSPORTER 1; FINASTERIDE; FOLINIC ACID; GLYCINE AMIDINOTRANSFERASE; GUANIDINOACETATE METHYLTRANSFERASE; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; ASPERGER SYNDROME; CHILD; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 22Q; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CLINICAL FEATURE; COPY NUMBER VARIATION; CREATINE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME DEFICIENCY; FAMILY HISTORY; FOLIC ACID DEFICIENCY; FRAGILE X SYNDROME; GENE MUTATION; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; INFANTILE AUTISM; MYOTONIC DYSTROPHY; NEUROFIBROMATOSIS; PHENOTYPE; PHENYLKETONURIA; REVIEW; SMITH LEMLI OPITZ SYNDROME; SUCCINATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; TUBEROUS SCLEROSIS; WILLIAMS BEUREN SYNDROME;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FRAGILE X SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; METABOLIC DISEASES; MYOTONIC DYSTROPHY; NEUROFIBROMATOSES; SYNDROME; TUBEROUS SCLEROSIS;

EID: 84856246384     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.10.014     Document Type: Review

References (86)

1. Bauman M.L. Medical comorbidities in autism: Challenges to diagnosis and treatment. Neurotherapeutics 2010, 7:320-327.
2. Bertoglio K., Hendren R.L. New developments in autism. Psychiatr Clin North Am 2009, 32:1-14.
3. Rice C. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, United States, 2006. MMWR Surveill Summ 2009, 58(10):1-20.
4. Schaefer G.B., Mendelsohn N.J., Professional Practice and Guidelines Committee Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med 2008, 10:301-305.
5. Schendel D.E., Autry A., Wines R., et al. The co-occurrence of autism and birth defects: prevalence and risk in a population-based cohort. Dev Med Child Neurol 2009, 51:779-786.
6. Atladottir H.O., Pedersen M.G., Scient C., et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009, 124:687-694.
7. Warren R.P., Odell J.D., Warren W.L., et al. Strong association of the third hypervariable region of the HLA-DR beta 1 with autism. JNeuroimmunol 1996, 67:97-102.
8. Reichenberg A., Gross R., Weiser M., et al. Advancing paternal age and autism. Arch Gen Psychiatry 1996, 63:1026-1032.
9. Cantor R.M., Yoon J.L., Furr J., et al. Paternal age and autism are associated in a family-based sample. Mol Psychiatry 2007, 12:419-421.
10. Croen L.A., Najjar D.V., Fireman B., et al. Maternal and paternal age and risk of autism spectrum disorders. Arch Pediatr Adolesc Med 2007, 161:334-340.
11. Anello A., Reichenberg A., Luo X., et al. Brief report: parental age and sex ratio in autism. JAutism Dev Disord 2009, 39:1487-1492.
12. Daniels J.L., Forssen U., Hultman C.M., et al. Parental psychiatric disorders associated with autism spectrum disorders in offspring. Pediatrics 2008, 121:1357-1362.
13. O'Roak B.J., Deriziotis P., Lee C., et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011, 43:585-589.
14. Schaefer G.B., Lutz R.E. Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders. Genet Med 2006, 8:549-556.
15. Kosinovsky B., Hermon S., Yoran-Hegesh R., et al. The yield of laboratory investigations in children with infantile autism. JNeural Transm 2005, 112:587-596.
16. Roesser J. Diagnostic yield of genetic testing in children diagnosed with autism spectrum disorders at a regional referral center. Clin Pediatr (Phila) 2011, 50(9):834-843. 10.1177/0009922811406261.
17. Benvenuto A., Manzi B., Alessandrelli R., et al. Recent advances in the pathogenesis of syndromic autisms. Int J Pediatr 2009, 2009:198736.
18. Shen Y., Dies K.A., Holm I.A., et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010, 125:727-735.
19. Herman G.E., Henninger N., Ratliff-Schaul K., et al. Genetic testing in autism: how much is enough?. Genet Med 2007, 9:268-274.
20. Battaglia A., Carey J.C. Etiologic yield of autistic spectrum disorders: a prospective study. Am J Med Genet 2006, 142C:3-7.
21. Boddaert N., Zilbovicius M., Philipe A., et al. MRI findings in 77 children with non-syndromic autistic disorder. PLoS One 2009, 4(2):e4415.
22. Betancur C. Etiologic heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 2011, 1380:42-77.
23. Miles J.H. Autism spectrum disorders-a genetics review. Genet Med 2011, 13:278-294.
24. Blau N., van Spronsen F.J., Levy H.L. Phenylketonuria. Lancet 2010, 376:1417-1427.
25. Reiss A.L., Feinstein C., Rosenbaum K.N. Autism in genetic disorders. Schizophr Bull 1986, 13:724-738.
26. Baieli S., Pavone L., Meli C., et al. Autism and phenylketonuria. JAutism Dev Disord 2003, 33:201-204.
27. Camici M., Micheli V., Ipata P.L., et al. Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int 2010, 56:367-378.
28. Jaeken J., Van den Berghe G. An infantile autistic syndrome characterized by the presence of succinylpurines in body fluid. Lancet 1984, 2:1058-1061.
29. Rogers M.H., Lwin R., Fairbanks L., et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. JPediatr 2001, 139:44-50.
30. Hettinger J.A., Liu X., Holden J.J.A. The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders. JAutism Dev Disord 2008, 38:14-19.
31. Bottini N., De Luca D., Saccucci P., et al. Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics 2001, 3:111-113.
32. Persico A.M., Militerni R., Bravaccio C., et al. Adenosine deaminase alleles and autistic disorder: case-control and family-based association studies. Am J Med Genet 2000, 96:784-790.
33. Knerr I., Gibson K.M., Jakobs C., et al. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr 2008, 13:598-605.
34. -/- mice and characterization of γ-hydroxybutyric acid pharmacology. JInherit Metab Dis 2007, 30:279-294.
35. Wang L., Angley M.T., Sorich M.J., et al. Is there a role for routinely screening children with autism spectrum disorder for creatine deficiency syndrome?. Autism Res 2010, 3:268-272.
36. Longo N., Ardon O., Vanzo R., et al. Disorders of creatine transport and metabolism. Am J Med Genet 2011, 157:72-78.
37. Schulze A. Creatine deficiency syndromes. Mol Cell Biochem 2003, 244:143-150.
38. Nasrallah F., Feki M., Kaabachi N. Creatine and creatine deficiency syndromes: biochemical and clinical aspects. Pediatr Neurol 2010, 42:163-171.
39. Hyland K., Shoffner J., Heales S.J. Cerebral folate deficiency. JInherit Metab Dis 2010, 33:563-570.
40. Ramaekers V.T., Hausler T., Opladen T., et al. Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 2002, 33:301-308.
41. Mangold S., Blau N., Opladen T., et al. Cerebral folate deficiency: a neurometabolic syndrome?. Mol Genet Metab 2011, [Epub ahead of print]. 10.1016/j.ymgme.2011.06.004.
42. Ramaekers V.T., Rothenberg S.P., Sequeira J.M., et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. NEngl J Med 2005, 352:1985-1991.
43. Moretti P., Peters S.U., del Gaudio D., et al. Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. JAutism Dev Disord 2008, 38:1170-1177.
44. Sikora D.M., Pettit-Kekel K., Penfield J., et al. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006, 140:1511-1518.
45. Tierney E., Bukelis I., Thompson R.E., et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:666-668.
46. Tamiji J., Crawford D.A. The neurobiology of lipid metabolism in autism spectrum disorders. Neurosignals 2010, 18:98-112.
47. Oliveira G., Diogo L., Grazina M., et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005, 47:185-189.
48. Weissman J.R., Kelley R.I., Bauman M.L., et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One 2008, 11:e3815.
49. Haas R.H. Autism and mitochondrial disease. Dev Disabil Res Rev 2010, 16:144-153.
50. Frye R.E., Rossignol D.A. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011, 69:41R-47R.
51. Suomalainen A. Therapy for mitochondrial disorders: little proof, high research activity, some promise. Sem Fetal Neonatal Med 2011, 16:236-240.
52. Miller D.T., Adam M.P., Aradhya S., et al. Consensus statement: chromosomal microarray is a first tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010, 86:749-764.
53. Van der Aa N., Rooms L., Vandeweyer G., et al. Fourteen new cases contribute to the characterization of the 7q11.23 microduplication syndrome. Eur J Med Genet 2009, 52:94-100.
54. Sakurai T., Dorr N.P., Takahashi N., et al. Haploinsufficiency of Gtf2i, a gene deleted in Williams syndrome, leads to increases in social interactions. Autism Res 2011, 4:28-39.
55. Sanders S.J., Ercan-Sencicek A.G., Hus V., et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011, 70:863-885.
56. Moreno-De-Luca D., SGENE Consortium, Mulle J.G., et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet 2010, 87:618-630.
57. McCarthy S.E., Makarov V., Kirov G., et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009, 41:1223-1227.
58. Miller D.T., Shen Y., Weiss L.A., et al. Microdeletion duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. JMed Genet 2009, 46:242-248.
59. Van Bon B.W., Mefford H.C., Menten B., et al. Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. JMed Genet 2009, 46:511-523.
60. Stefansson H., Rujescu D., Cichon S., et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:178-179.
61. Cusmano-Ozog K., Manning M.A., Hoyme H.E. 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. Am J Med Genet C Semin Med Genet 2007, 145C:393-398.
62. Dhar S.U., del Gaudio D., German J.R., et al. 22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A 2010, 152A:573-581.
63. Friedman J.M. Neurofibromatosis 1. Genereviews 2009, (internet), University of WA, Seattle (WA). R.A. Pagon, T.D. Bird, C.R. Dolan (Eds.).
64. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD, USA, July 13-15, 1987. Neurofibromatosis 1988, 1:172-178.
65. DeBella K., Szudek J., Friedman J.M. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000, 105:608-614.
66. Mandell D.S., Novak M.M., Zubritsky C.D. Factors associated with age of diagnosis among children with autism spectrum disorders. Pediatrics 2005, 116:1480-1486.
67. Smalley S.L. Autism and tuberous sclerosis. JAutism Dev Disord 1998, 28:407-414.
68. Numis A.L., Major P., Montenegro M.A., et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011, 76:981-987.
69. Fombonne E., Du Mazaubrun C., Cans C., et al. Autism and associated medical disorders in a French epidemiological survey. JAm Acad Child Adolesc Psychiatry 1997, 36:1561-1569.
70. Roach E.S., Sparagnana S.P. Diagnosis of tuberous sclerosis complex. JChild Neurol 2004, 19:643-649.
71. Bird T.D. Myotonic dystrophy type 1. Genereviews 2011, (internet), University of WA, Seattle (WA). R.A. Pagon, T.D. Bird, C.R. Dolan (Eds.).
72. Ekstrom A.B., Hakenas-Plate L., Samuelsson L., et al. Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:918-926.
73. Blondis T.A., Cook E., Koza-Taylor P., et al. Asperger syndrome associated with Steinert's myotonic dystrophy. Dev Med Child Neurol 1996, 38:840-847.
74. Coffee B., Keith K., Albizua I., et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009, 85:503-514.
75. Curry C.J., Stevenson R.E., Aughton D., et al. Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics. Am J Med Genet 1997, 12:468-477.
76. Rauch A., Hoyer J., Guth S., et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006, 140:2063-2074.
77. Hatton D.D., Sideris J., Skinner M., et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006, 140:1804-1813.
78. Hagerman R., Au J., Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. JNeurodev Disord 2011, 3(3):211-224. 10.1007/s11689-011-9084-5.
79. Farzin F., Perry H., Hessl D., et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. JDev Behav Pediatr 2006, 27:S137-S143.
80. Bailey D.B., Raspa M., Olmsted M., et al. Co-occurring conditions associated with FMR1 gene variations; findings from a national parent survey. Am J Med Genet A 2008, 146:2060-2069.
81. Scherer S.W., Dawson G. Risk factors for autism: translating genomic discoveries into diagnostics. Hum Genet 2011, 130:123-148.
82. Johnson C.P., Myers S.M. Council on Children with Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007, 120:1183-1215.
83. Filipek P.A., Accardo P.J., Ashwal S., et al. Practice parameter: screening and diagnosis of autism: report of the quality standards subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000, 44:468-479.
84. Rapin I. Appropriate investigations for clinical care versus research in children with autism. Brain Dev 1999, 21:152-156.
85. Bockenhauer D., Medlar A.J., Ashton E., et al. Genetic testing in renal disease. Pediatr Nephrol 2011, [Epub ahead of print]. 10.1007/s00467-011-1865-2.
86. McPherson E. Genetic diagnosis and testing in clinical practice. Clin Med Res 2006, 4:123-129.